Drug Discovery

#AstraZeneca #Covid-19 #Drug development #Immunology / Virology & Vaccines #Moderna #Pfizer

COVID-19 booster shots more likely than vaccines due to variants

Data analytics company, GlobalData says that if new SARS-CoV-2 variants continue to develop, reducing the effectiveness of COVID-19 vaccines and the natural immunity of survivors, then annual booster shots may be required for COVID-19 immunity. Johanna Swanson, Product Manager at GlobalData, said: “Of the several natural variants that have recently been… Read More

#Covid-19 #News

#Cancer research #Diagnostics #Drug development #In vitro

Avacta enters diagnostic licensing deal with Biokit

Avacta, developer of cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, has announced a licensing agreement with Biokit, to incorporate Affimer reagents into a Biokit in-vitro diagnostic (IVD) product. Biokit has experience in research, development and manufacturing of assays and biomaterial solutions for IVD use. Under… Read More

#Cancer Research #News

#Brain disease #Drug development #Drug discovery #Screening

Human cerebral organoid used to test drug for fatal brain disease

After establishing a human cerebral organoid system to study Creutzfeldt-Jakob disease (CJD), National Institutes of Health researchers have further developed the model to screen drugs for potential CJD treatment. CJD, a fatal neurodegenerative brain disease of humans caused by infectious prion proteins, affects about 1 in a million people annually. Read More

#News

#Cancer research #Drug development #Drug discovery #Genes

New study able to detect BRCA1 breast cells before they turn cancerous

The earliest changes that occur in seemingly healthy breast tissue before tumours appear may have been found by researchers, suggests a new study published in Nature Communications. The study in mice, funded by Cancer Research UK, showed that before becoming cancerous, breast cells with the BRCA1 gene mutation undergo changes similar… Read More

#Cancer Research #News

#Biologics / Biotechnology #Cancer immunotherapy #Cancer research #Drug development

Pathios Therapeutics boosted with Innovate UK funding

Pathios, a biotech company focused on the development of first-in-class therapies for cancer, announced that it has been awarded £350K in the form of a Smart Grant from Innovate UK. The UK government innovation agency’s money will accelerate Pathios’ cancer immunotherapy programme which targets the innate immune checkpoint, GPR65. Pathios… Read More

#Cancer Research #News

#Compounds #Drug discovery #Pharmaceuticals

A guide to fragment-based drug discovery

Fragment-based drug discovery (FBDD) is one of the most popular approaches for finding lead compounds and it is becoming more widely adopted by pharma companies. FBDD is the solution researchers turn to when faced with challenging targets that call for compound libraries that offer more diverse molecules — especially from… Read More

#News

#Biopharmaceuticals #Biotechnology #Drug delivery #Drug development

Amryt and Medison distribution agreement for metreleptin in Canada

Global biopharmaceutical company Amryt has signed a distribution agreement with Medison Pharma Canada to distribute Myalepta (metreleptin) in Canada. Amryt is a global, commercial-stage biopharmaceutical company focused on acquiring, developing and commercialising novel treatments for rare diseases. Medison is a commercial partner of global biotech companies that provide integrated services… Read More

#News

#AstraZeneca #Biopharmaceuticals #Drug delivery #Drug development

Aptamer Group extends AstraZeneca collaboration

UK reagents and therapeutics developer, Aptamer Group has extended its current agreement with global biopharmaceutical company AstraZeneca. This agreement will build upon the existing collaboration to evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates. Optimers… Read More

#Editor's Choice #News #Trending News

#Biomarkers #Clinical trials #Drug development #Metabolomics #Metabolon

Life science companies collaborate for drug development

Metabolon and Cleveland Clinic have entered into multi-year collaborative agreement to accelerate research, drug development and precision medicine. Metabolon will leverage its proprietary platform to analyse a range of biologic samples to help discover metabolomic biomarkers that will deepen understanding of Cleveland Clinic’s novel discoveries, improve speed of decision-making and… Read More

#News

#Assay #Assay development & optimisation #Drug discovery

BioIVT to supply PBMCs for new bioassay

BioIVT, provider of research models and services for drug and diagnostic development, is supplying peripheral blood mononuclear cells (PBMCs) for Promega’s antibody-dependent Cellular Cytotoxicity (ADCC) bioassay bioassay, which uses PBMCs to mimic in vivo conditions and measure the ADCC of antibodies during drug development and characterisation. “This new platform combines BioIVT’s high… Read More

#News

#AI / data analytics / healthtech / informatics #Drug discovery #Finance #Pharmatech

$100 million invested in AI development

Clinical pharmatech company Exscientia’s Series C financing round was completed with investment of $30 million from BlackRock, which will accelerate its AI drug discovery platform and pipeline. Blackrock funds joined Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital in the investment $100 million round. New capital will be… Read More

#News

#Drug discovery #Events #Protein misfolding

Wren Therapeutics & University of Florida at Targeting Protein Misfolding 2021

In the field of drug discovery, so called ‘undruggable’ targets are like the stubborn children of the protein world – notoriously difficult to find, and even harder to target. For undruggable protein misfolding diseases such as Alzheimer’s and Parkinson’s, traditional drug discovery and biological approaches have, to date, proved largely… Read More

#News

#Cancer research #Drug development #Therapeutics

Vivan Therapeutics joins global Repositive Cancer Model network

Repositive has announced that UK-based personalised therapeutics company Vivan Therapeutics will join its network of cancer model partners. Vivan Therapeutics is a personalised therapeutics company that engineers drosophila ‘avatar’ models for cancer research and development. Its technology engineers the genetic complexity of a cancer patient’s unique tumour network (up to… Read More

#Cancer Research #News

#Drug development #Drug discovery #Gene therapy #Therapeutics

Geneticist launches Axovia Therapeutics to develop medicines for ciliopathies

Axovia Therapeutics, a gene therapy company developing disease-transformative medicines for ciliopathies, led by researcher Professor Philip Beales, has launched after being in stealth mode for the past year. Axovia is a majority-owned subsidiary of Jaguar Gene Therapy, and is partially funded by UCL Technology Fund. Axovia is receiving initial operational… Read More

#Editor's Choice #News

#Diagnostics #Drug development #Drug discovery #Webinar

Why hepatocytes are enabling antimalarial drug discovery

BioIVT, providers of research models and services for drug and diagnostic development, will be hosting a webinar where researchers from the University of Georgia will explain the first medium-throughput, 384-well plate-based liver-stage antimalarial drug discovery platform which they have developed. The webinar, entitled Identifying the Critical Factors Enabling a Phenotypic… Read More

#News